Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.

Nicolas A Menzies; Gabriela B Gomez; Fiammetta Bozzani ORCID logo; Susmita Chatterjee; Nicola Foster ORCID logo; Ines Garcia Baena; Yoko V Laurence ORCID logo; Sun Qiang; Andrew Siroka; Sedona Sweeney ORCID logo; +46 more... Stéphane Verguet; Nimalan Arinaminpathy; Andrew S Azman; Eran Bendavid; Stewart T Chang; Ted Cohen; Justin T Denholm; David W Dowdy; Philip A Eckhoff; Jeremy D Goldhaber-Fiebert; Andreas Handel; Grace H Huynh; Marek Lalli; Hsien-Ho Lin; Sandip Mandal; Emma S McBryde; Surabhi Pandey; Joshua A Salomon; Sze-Chuan Suen; Tom Sumner ORCID logo; James M Trauer; Bradley G Wagner; Christopher C Whalen; Chieh-Yin Wu; Delia Boccia ORCID logo; Vineet K Chadha; Salome Charalambous; Daniel P Chin; Gavin Churchyard; Colleen Daniels; Puneet Dewan; Lucica Ditiu; Jeffrey W Eaton; Alison D Grant ORCID logo; Piotr Hippner; Mehran Hosseini; David Mametja; Carel Pretorius; Yogan Pillay; Kiran Rade; Suvanand Sahu; Lixia Wang; Rein MGJ Houben ORCID logo; Michael E Kimerling; Richard G White ORCID logo; Anna Vassall ORCID logo; (2016) Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global health, 4 (11). e816-e826. ISSN 2214-109X DOI: 10.1016/S2214-109X(16)30265-0
Copy

BACKGROUND: The post-2015 End TB Strategy sets global targets of reducing tuberculosis incidence by 50% and mortality by 75% by 2025. We aimed to assess resource requirements and cost-effectiveness of strategies to achieve these targets in China, India, and South Africa. METHODS: We examined intervention scenarios developed in consultation with country stakeholders, which scaled up existing interventions to high but feasible coverage by 2025. Nine independent modelling groups collaborated to estimate policy outcomes, and we estimated the cost of each scenario by synthesising service use estimates, empirical cost data, and expert opinion on implementation strategies. We estimated health effects (ie, disability-adjusted life-years averted) and resource implications for 2016-35, including patient-incurred costs. To assess resource requirements and cost-effectiveness, we compared scenarios with a base case representing continued current practice. FINDINGS: Incremental tuberculosis service costs differed by scenario and country, and in some cases they more than doubled existing funding needs. In general, expansion of tuberculosis services substantially reduced patient-incurred costs and, in India and China, produced net cost savings for most interventions under a societal perspective. In all three countries, expansion of access to care produced substantial health gains. Compared with current practice and conventional cost-effectiveness thresholds, most intervention approaches seemed highly cost-effective. INTERPRETATION: Expansion of tuberculosis services seems cost-effective for high-burden countries and could generate substantial health and economic benefits for patients, although substantial new funding would be required. Further work to determine the optimal intervention mix for each country is necessary. FUNDING: Bill & Melinda Gates Foundation.


picture_as_pdf
1-s2.0-S2214109X16302650-main.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads